Patents by Inventor John Krystal

John Krystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER
    Publication number: 20240082215
    Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 14, 2024
    Applicants: Novartis AG, Yale University
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA, John KRYSTAL, Vincent MALATERRE, Stephanie O'MALLEY, Godfrey PEARLSON, Marc POTENZA
  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20240033254
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 1, 2024
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Combination therapy for treating or preventing depression or other mood diseases
    Patent number: 11793794
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: October 24, 2023
    Assignees: YALE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20230070600
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 9, 2023
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20210251969
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: August 20, 2019
    Publication date: August 19, 2021
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Intranasal Administration of Ketamine to Treat Depression
    Publication number: 20070287753
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: March 20, 2007
    Publication date: December 13, 2007
    Applicants: MOUNT SINAI SCHOOL OF MEDICINE, NATIONAL INSTITUTE OF HEALTH, YALE UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Dennis Charney, Sanjay Mathew, Husseini Manji, Carlos Zarate, John Krystal
  • Glutamate agents in the treatment of mental disorders
    Publication number: 20060270647
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 30, 2006
    Applicant: Yale University
    Inventors: Vladimir Coric, John Krystal, Gerard Sanacora